2-hexyldecanoic acid: viscous oil
ID Source | ID |
---|---|
PubMed CID | 32912 |
CHEMBL ID | 3182660 |
CHEBI ID | 135056 |
SCHEMBL ID | 112804 |
MeSH ID | M0350368 |
Synonym |
---|
brn 1777217 |
einecs 246-885-9 |
7-pentadecanecarboxylic acid |
2-hexyldecansaeure [german] |
2-hexyldecanoic acid |
decanoic acid, 2-hexyl- |
2-hexyldecanoic acid, 96% |
2-hexyl-decanoic acid |
LMFA01020166 |
CHEBI:135056 |
hexyldecanoic acid |
25354-97-6 |
pentadecane-7-carboxylic acid |
H0507 |
dtxsid7044893 , |
cas-25354-97-6 |
NCGC00256308-01 |
dtxcid5024893 |
tox21_301670 |
2-hexyldecansaeure |
4-02-00-01189 (beilstein handbook reference) |
49m19xfi8b , |
2-h-da |
unii-49m19xfi8b |
FT-0613153 |
FT-0612496 |
AKOS015894408 |
isocarb 16 |
jaric i-16 |
hexyldecanoic acid [inci] |
isocarb 16 acid |
(+/-)-2-hexyldecanoic acid |
2-hexyldecanoic acid, (+/-)- |
2-hexyldecanoic acid [mi] |
ch3(ch2)7ch(c6h13)cooh |
2-hexyl-1-decanoic acid |
SCHEMBL112804 |
2-n-hexyldecanoic acid |
W-110625 |
CHEMBL3182660 |
mfcd00059651 |
SY050048 |
AC8879 |
Q27259295 |
AS-57406 |
BP-31086 |
EN300-18536040 |
CS-0152274 |
HY-W099632 |
Class | Description |
---|---|
medium-chain fatty acid | Any fatty acid with a chain length of between C6 and C12. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 49.2911 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 24.3365 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 0.2434 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 9.6885 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
progesterone receptor | Homo sapiens (human) | Potency | 68.5896 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 38.8952 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 14.1950 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 36.5316 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259403 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 20.6900 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 14.6425 | 0.0010 | 19.4141 | 70.9645 | AID743140; AID743191 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 54.4827 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 48.9662 | 19.7391 | 45.9784 | 64.9432 | AID1159518 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 15.8212 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 24.3365 | 0.0003 | 23.4451 | 159.6830 | AID743065 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 40.4463 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.85) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (16.67%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (16.67%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (66.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |